Posted by Michael Wonder on 20 Feb 2024
argenx announces FDA acceptance of supplemental biologics license application with priority review for Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy
20 February 2024 - Prescription Drug User Fee Act target action date is 21 June 2024.
argenx today announced that the US FDA has accepted for priority review a supplemental biologics license application for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of chronic inflammatory demyelinating polyneuropathy.
